By: original industry insider
PFE heavy in after hours trading. Word on The Street is too close to call. http://finance.yahoo.com/news/most-active-york-stock-exchange-172313205.html
View ArticleBy: TonyDewitt
The hidden surprise in tofacitinib is that since it is a JAK inhibitor, it is effective against two disorders caused by HTLV: HAM and ATL. Once the drug is approved, 25 million HTLV sufferers will ask...
View ArticleBy: TonyDewitt
Xeljanz (tofacitinib) has been approved on November 7th, 2012 – the hidden surprise is that it is effective against two disorders caused by HTLV: HAM and ATL. Since there are WAY more HTLV sufferers...
View Article
More Pages to Explore .....
